These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19035415)

  • 1. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
    Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
    Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
    Syngle A; Vohra K; Kaur L; Sharma S
    Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
    Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
    Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
    Dahlqvist SR; Engstrand S; Berglin E; Johnson O
    Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis.
    McGonagle D; Tan AL; Madden J; Taylor L; Emery P
    Rheumatology (Oxford); 2008 Jun; 47(6):865-7. PubMed ID: 18390581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.
    Thurlings RM; Vos K; Gerlag DM; Tak PP
    Arthritis Rheum; 2008 Dec; 58(12):3657-64. PubMed ID: 19035505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.
    Kerekes G; Szekanecz Z; Dér H; Sándor Z; Lakos G; Muszbek L; Csipö I; Sipka S; Seres I; Paragh G; Kappelmayer J; Szomják E; Veres K; Szegedi G; Shoenfeld Y; Soltész P
    J Rheumatol; 2008 Mar; 35(3):398-406. PubMed ID: 18203326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
    Wong M; Oakley SP; Young L; Jiang BY; Wierzbicki A; Panayi G; Chowienczyk P; Kirkham B
    Ann Rheum Dis; 2009 Aug; 68(8):1277-84. PubMed ID: 18930987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.
    Gonzalez-Juanatey C; Testa A; Garcia-Castelo A; Garcia-Porrua C; Llorca J; Gonzalez-Gay MA
    Arthritis Rheum; 2004 Jun; 51(3):447-50. PubMed ID: 15188332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
    Nasonov EL; Lukina GV; Sigidin IaA; Bazevich LA; Zlobina TI; Kamalova RG; Kniazeva LA; Mazurov VI; Men'shikova LV; Sizikov AE; Smirnova EA; Fofonova NA; Shabalina TV; Shkil' NV; Iakushin SS
    Ter Arkh; 2008; 80(8):57-62. PubMed ID: 18807543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment.
    Foster W; Carruthers D; Lip GY; Blann AD
    J Rheumatol; 2010 Apr; 37(4):711-6. PubMed ID: 20156948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.